BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dogan B, Scherl E, Bosworth B, Yantiss R, Altier C, McDonough PL, Jiang ZD, Dupont HL, Garneau P, Harel J, Rishniw M, Simpson KW. Multidrug resistance is common in Escherichia coli associated with ileal Crohn's disease. Inflamm Bowel Dis. 2013;19:141-150. [PMID: 22508665 DOI: 10.1002/ibd.22971] [Cited by in Crossref: 36] [Cited by in F6Publishing: 44] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Martinez-Medina M, Strozzi F, Castillo BRD, Serrano-Morillas N, Bustins NF, Martínez-Martínez L. Antimicrobial Resistance Profiles of Adherent Invasive Escherichia coli Show Increased Resistance to β-Lactams. Antibiotics (Basel) 2020;9:E251. [PMID: 32414140 DOI: 10.3390/antibiotics9050251] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
2 Vila J, Sáez-López E, Johnson JR, Römling U, Dobrindt U, Cantón R, Giske CG, Naas T, Carattoli A, Martínez-Medina M, Bosch J, Retamar P, Rodríguez-Baño J, Baquero F, Soto SM. Escherichia coli: an old friend with new tidings. FEMS Microbiol Rev 2016;40:437-63. [PMID: 28201713 DOI: 10.1093/femsre/fuw005] [Cited by in Crossref: 108] [Cited by in F6Publishing: 82] [Article Influence: 27.0] [Reference Citation Analysis]
3 Oberc AM, Fiebig-Comyn AA, Tsai CN, Elhenawy W, Coombes BK. Antibiotics Potentiate Adherent-Invasive E. coli Infection and Expansion. Inflamm Bowel Dis 2019;25:711-21. [PMID: 30496418 DOI: 10.1093/ibd/izy361] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
4 Chen H, Wang X, Wang L, Liu H, Yin Y. Ileocecal lavage fluid for gut microbiota investigation in children with gastrointestinal diseases. Gastroenterology Report 2021. [DOI: 10.1093/gastro/goab044] [Reference Citation Analysis]
5 Khan AA, Khan Z, Malik A, Kalam MA, Cash P, Ashraf MT, Alshamsan A. Colorectal cancer-inflammatory bowel disease nexus and felony of Escherichia coli. Life Sci. 2017;180:60-67. [PMID: 28506682 DOI: 10.1016/j.lfs.2017.05.016] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
6 Dogan B, Fu J, Zhang S, Scherl EJ, Simpson KW. Rifaximin decreases virulence of Crohn's disease-associated Escherichia coli and epithelial inflammatory responses. J Antibiot (Tokyo) 2018;71:485-94. [PMID: 29410518 DOI: 10.1038/s41429-017-0022-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
7 Xia Y, Wang J, Fang X, Dou T, Han L, Yang C. Combined analysis of metagenomic data revealed consistent changes of gut microbiome structure and function in inflammatory bowel disease. J Appl Microbiol 2021. [PMID: 34008889 DOI: 10.1111/jam.15154] [Reference Citation Analysis]
8 Camprubí-Font C, Bustamante P, Vidal RM, O'Brien CL, Barnich N, Martinez-Medina M. Study of a classification algorithm for AIEC identification in geographically distinct E. coli strains. Sci Rep 2020;10:8094. [PMID: 32415168 DOI: 10.1038/s41598-020-64894-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Bonfiglio G, Neroni B, Radocchia G, Pompilio A, Mura F, Trancassini M, Di Bonaventura G, Pantanella F, Schippa S. Growth Control of Adherent-Invasive Escherichia coli (AIEC) by the Predator Bacteria Bdellovibrio bacteriovorus: A New Therapeutic Approach for Crohn's Disease Patients. Microorganisms 2019;8:E17. [PMID: 31861852 DOI: 10.3390/microorganisms8010017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
10 Abdelhalim KA, Uzel A, Ünal NG. The role of major virulence factors and pathogenicity of adherent-invasive Escherichia coli in patients with Crohn's disease. Prz Gastroenterol 2020;15:279-88. [PMID: 33777266 DOI: 10.5114/pg.2020.93235] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Renouf MJ, Cho YH, McPhee JB. Emergent Behavior of IBD-Associated Escherichia coli During Disease. Inflamm Bowel Dis 2019;25:33-44. [PMID: 30321333 DOI: 10.1093/ibd/izy312] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
12 Viladomiu M, Kivolowitz C, Abdulhamid A, Dogan B, Victorio D, Castellanos JG, Woo V, Teng F, Tran NL, Sczesnak A, Chai C, Kim M, Diehl GE, Ajami NJ, Petrosino JF, Zhou XK, Schwartzman S, Mandl LA, Abramowitz M, Jacob V, Bosworth B, Steinlauf A, Scherl EJ, Wu HJ, Simpson KW, Longman RS. IgA-coated E. coli enriched in Crohn's disease spondyloarthritis promote TH17-dependent inflammation. Sci Transl Med 2017;9:eaaf9655. [PMID: 28179509 DOI: 10.1126/scitranslmed.aaf9655] [Cited by in Crossref: 149] [Cited by in F6Publishing: 131] [Article Influence: 29.8] [Reference Citation Analysis]
13 Rakitina DV, Manolov AI, Kanygina AV, Garushyants SK, Baikova JP, Alexeev DG, Ladygina VG, Kostryukova ES, Larin AK, Semashko TA, Karpova IY, Babenko VV, Ismagilova RK, Malanin SY, Gelfand MS, Ilina EN, Gorodnichev RB, Lisitsyna ES, Aleshkin GI, Scherbakov PL, Khalif IL, Shapina MV, Maev IV, Andreev DN, Govorun VM. Genome analysis of E. coli isolated from Crohn's disease patients. BMC Genomics 2017;18:544. [PMID: 28724357 DOI: 10.1186/s12864-017-3917-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
14 Nadalian B, Yadegar A, Houri H, Olfatifar M, Shahrokh S, Asadzadeh Aghdaei H, Suzuki H, Zali MR. Prevalence of the pathobiont adherent-invasive Escherichia coli and inflammatory bowel disease: a systematic review and meta-analysis. J Gastroenterol Hepatol 2021;36:852-63. [PMID: 32929762 DOI: 10.1111/jgh.15260] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
15 Kothary V, Scherl EJ, Bosworth B, Jiang ZD, Dupont HL, Harel J, Simpson KW, Dogan B. Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps. Antimicrob Agents Chemother. 2013;57:811-817. [PMID: 23183443 DOI: 10.1128/aac.02163-12] [Cited by in Crossref: 41] [Cited by in F6Publishing: 20] [Article Influence: 4.1] [Reference Citation Analysis]
16 Camprubí-Font C, Lopez-Siles M, Ferrer-Guixeras M, Niubó-Carulla L, Abellà-Ametller C, Garcia-Gil LJ, Martinez-Medina M. Comparative genomics reveals new single-nucleotide polymorphisms that can assist in identification of adherent-invasive Escherichia coli. Sci Rep 2018;8:2695. [PMID: 29426864 DOI: 10.1038/s41598-018-20843-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
17 Sarabi Asiabar A, Asadzadeh Aghdaei H, Sabokbar A, Zali MR, Feizabadi MM. Investigation of adherent-invasive E. coli in patients with Crohn's disease. Med J Islam Repub Iran 2018;32:11. [PMID: 30159262 DOI: 10.14196/mjiri.32.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 da Silva Santos AC, Gomes Romeiro F, Yukie Sassaki L, Rodrigues J. Escherichia coli from Crohn's disease patient displays virulence features of enteroinvasive (EIEC), enterohemorragic (EHEC), and enteroaggregative (EAEC) pathotypes. Gut Pathog 2015;7:2. [PMID: 25653719 DOI: 10.1186/s13099-015-0050-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
19 Abdelhalim KA, Uzel A, Gülşen Ünal N. Virulence determinants and genetic diversity of adherent-invasive Escherichia coli (AIEC) strains isolated from patients with Crohn's disease. Microb Pathog 2020;145:104233. [PMID: 32360521 DOI: 10.1016/j.micpath.2020.104233] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
20 Longman RS, Swaminath A. Microbial manipulation as primary therapy for Crohn's disease. World J Gastroenterol 2013; 19(10): 1513-1516 [PMID: 23539531 DOI: 10.3748/wjg.v19.i10.1513] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
21 Flanagan PK, Chiewchengchol D, Wright HL, Edwards SW, Alswied A, Satsangi J, Subramanian S, Rhodes JM, Campbell BJ. Killing of Escherichia coli by Crohn's Disease Monocyte-derived Macrophages and Its Enhancement by Hydroxychloroquine and Vitamin D. Inflamm Bowel Dis 2015;21:1499-510. [PMID: 25839777 DOI: 10.1097/MIB.0000000000000387] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
22 Cieplak T, Soffer N, Sulakvelidze A, Nielsen DS. A bacteriophage cocktail targeting Escherichia coli reduces E. coli in simulated gut conditions, while preserving a non-targeted representative commensal normal microbiota. Gut Microbes 2018;9:391-9. [PMID: 29517960 DOI: 10.1080/19490976.2018.1447291] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
23 Manchester AC, Dogan B, Guo Y, Simpson KW. Escherichia coli-associated granulomatous colitis in dogs treated according to antimicrobial susceptibility profiling. J Vet Intern Med 2021;35:150-61. [PMID: 33321554 DOI: 10.1111/jvim.15995] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Zhilu X, Xiangqian D, Keli Y, Caroline C, Jingwan Z, Yu L, Tao Z, Cheung CL, Yang S, Fengrui Z, Kl CF, Jy SJ, Jun Y, Anthony B, Nicolas B, Jean-Frédéric C, Sunny Hei W, Yinglei M, Siew C N. Association of Adherent-invasive Escherichia coli with severe Gut Mucosal dysbiosis in Hong Kong Chinese population with Crohn's disease. Gut Microbes 2021;13:1994833. [PMID: 34812117 DOI: 10.1080/19490976.2021.1994833] [Reference Citation Analysis]
25 Ledder O, Turner D. Antibiotics in IBD: Still a Role in the Biological Era? Inflamm Bowel Dis. 2018;24:1676-1688. [PMID: 29722812 DOI: 10.1093/ibd/izy067] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 9.3] [Reference Citation Analysis]
26 Wang J, Bleich RM, Zarmer S, Zhang S, Dogan B, Simpson KW, Arthur JC. Long-read sequencing to interrogate strain-level variation among adherent-invasive Escherichia coli isolated from human intestinal tissue. PLoS One 2021;16:e0259141. [PMID: 34710159 DOI: 10.1371/journal.pone.0259141] [Reference Citation Analysis]
27 Ledder O. Antibiotics in inflammatory bowel diseases: do we know what we're doing? Transl Pediatr 2019;8:42-55. [PMID: 30881898 DOI: 10.21037/tp.2018.11.02] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
28 Cochran L, Hill S, Lotti U, Allenspach K, Palma D, Forman M, Gary AT, Dogan B, McDonough SP, Simpson KW. Clinical characteristics and long-term outcome of E. coli-associated granulomatous ileocolitis in dogs: five cases (2010-2014). J Small Anim Pract 2021;62:588-98. [PMID: 33660270 DOI: 10.1111/jsap.13313] [Reference Citation Analysis]
29 Kamali Dolatabadi R, Feizi A, Halaji M, Fazeli H, Adibi P. The Prevalence of Adherent-Invasive Escherichia coli and Its Association With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Front Med (Lausanne) 2021;8:730243. [PMID: 34926490 DOI: 10.3389/fmed.2021.730243] [Reference Citation Analysis]
30 Siniagina MN, Markelova MI, Boulygina EA, Laikov AV, Khusnutdinova DR, Abdulkhakov SR, Danilova NA, Odintsova AH, Abdulkhakov RA, Grigoryeva TV. Diversity and Adaptations of Escherichia coli Strains: Exploring the Intestinal Community in Crohn's Disease Patients and Healthy Individuals. Microorganisms 2021;9:1299. [PMID: 34203637 DOI: 10.3390/microorganisms9061299] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Camprubí-Font C, Ewers C, Lopez-Siles M, Martinez-Medina M. Genetic and Phenotypic Features to Screen for Putative Adherent-Invasive Escherichia coli. Front Microbiol 2019;10:108. [PMID: 30846972 DOI: 10.3389/fmicb.2019.00108] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
32 Elhenawy W, Hordienko S, Gould S, Oberc AM, Tsai CN, Hubbard TP, Waldor MK, Coombes BK. High-throughput fitness screening and transcriptomics identify a role for a type IV secretion system in the pathogenesis of Crohn's disease-associated Escherichia coli. Nat Commun 2021;12:2032. [PMID: 33795670 DOI: 10.1038/s41467-021-22306-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
33 Zhang S, Dogan B, Guo C, Herlekar D, Stewart K, Scherl EJ, Simpson KW. Short Chain Fatty Acids Modulate the Growth and Virulence of Pathosymbiont Escherichia coli and Host Response. Antibiotics (Basel) 2020;9:E462. [PMID: 32751519 DOI: 10.3390/antibiotics9080462] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
34 Palmela C, Chevarin C, Xu Z, Torres J, Sevrin G, Hirten R, Barnich N, Ng SC, Colombel JF. Adherent-invasive Escherichia coli in inflammatory bowel disease. Gut 2018;67:574-87. [PMID: 29141957 DOI: 10.1136/gutjnl-2017-314903] [Cited by in Crossref: 199] [Cited by in F6Publishing: 175] [Article Influence: 49.8] [Reference Citation Analysis]
35 Zhang Y, Rowehl L, Krumsiek JM, Orner EP, Shaikh N, Tarr PI, Sodergren E, Weinstock GM, Boedeker EC, Xiong X, Parkinson J, Frank DN, Li E, Gathungu G. Identification of Candidate Adherent-Invasive E. coli Signature Transcripts by Genomic/Transcriptomic Analysis. PLoS One. 2015;10:e0130902. [PMID: 26125937 DOI: 10.1371/journal.pone.0130902] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
36 Chervy M, Barnich N, Denizot J. Adherent-Invasive E. coli: Update on the Lifestyle of a Troublemaker in Crohn's Disease. Int J Mol Sci 2020;21:E3734. [PMID: 32466328 DOI: 10.3390/ijms21103734] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
37 Tawfik A, Flanagan PK, Campbell BJ. Escherichia coli-host macrophage interactions in the pathogenesis of inflammatory bowel disease. World J Gastroenterol 2014; 20(27): 8751-8763 [PMID: 25083050 DOI: 10.3748/wjg.v20.i27.8751] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
38 Oberc A, Coombes BK. Convergence of External Crohn's Disease Risk Factors on Intestinal Bacteria. Front Immunol 2015;6:558. [PMID: 26579131 DOI: 10.3389/fimmu.2015.00558] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
39 Martinez-Medina M, Garcia-Gil LJ. Escherichia coli in chronic inflammatory bowel diseases: An update on adherent invasive Escherichia coli pathogenicity. World J Gastrointest Pathophysiol 2014; 5(3): 213-227 [PMID: 25133024 DOI: 10.4291/wjgp.v5.i3.213] [Cited by in CrossRef: 100] [Cited by in F6Publishing: 99] [Article Influence: 12.5] [Reference Citation Analysis]
40 Agus A, Massier S, Darfeuille-Michaud A, Billard E, Barnich N. Understanding host-adherent-invasive Escherichia coli interaction in Crohn's disease: opening up new therapeutic strategies. Biomed Res Int 2014;2014:567929. [PMID: 25580435 DOI: 10.1155/2014/567929] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 4.5] [Reference Citation Analysis]
41 Lopetuso LR, Napoli M, Rizzatti G, Gasbarrini A. The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn’s disease. Expert Opinion on Investigational Drugs 2018;27:543-51. [DOI: 10.1080/13543784.2018.1483333] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
42 Mayorgas A, Dotti I, Martínez-Picola M, Esteller M, Bonet-Rossinyol Q, Ricart E, Salas A, Martínez-Medina M. A Novel Strategy to Study the Invasive Capability of Adherent-Invasive Escherichia coli by Using Human Primary Organoid-Derived Epithelial Monolayers. Front Immunol 2021;12:646906. [PMID: 33854511 DOI: 10.3389/fimmu.2021.646906] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
43 Sivignon A, Bouckaert J, Bernard J, Gouin SG, Barnich N. The potential of FimH as a novel therapeutic target for the treatment of Crohn’s disease. Expert Opinion on Therapeutic Targets 2017;21:837-47. [DOI: 10.1080/14728222.2017.1363184] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
44 Small CL, Xing L, McPhee JB, Law HT, Coombes BK. Acute Infectious Gastroenteritis Potentiates a Crohn's Disease Pathobiont to Fuel Ongoing Inflammation in the Post-Infectious Period. PLoS Pathog. 2016;12:e1005907. [PMID: 27711220 DOI: 10.1371/journal.ppat.1005907] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
45 Aygun H, Karamese M, Ozic C, Uyar F. The effects of mucosal media on some pathogenic traits of Crohn's disease-associated Escherichia coli LF82. Future Microbiology 2018;13:141-9. [DOI: 10.2217/fmb-2017-0133] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
46 Camprubí-Font C, Martinez-Medina M. Why the discovery of adherent-invasive Escherichia coli molecular markers is so challenging? World J Biol Chem 2020; 11(1): 1-13 [PMID: 32405343 DOI: 10.4331/wjbc.v11.i1.1] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
47 Sartor RB. Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases. Aliment Pharmacol Ther. 2016;43 Suppl 1:27-36. [PMID: 26618923 DOI: 10.1111/apt.13436] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
48 Vasovic M, Gajovic N, Brajkovic D, Jovanovic M, Zdravkovaic N, Kanjevac T. The relationship between the immune system and oral manifestations of inflammatory bowel disease: a review. Cent Eur J Immunol. 2016;41:302-310. [PMID: 27833449 DOI: 10.5114/ceji.2016.63131] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
49 Meheissen M, Header D, Abdelaty K. Phylogenetic and pathotype analysis of Escherichia coli stool isolates from Egyptian patients with inflammatory bowel disease. Germs 2019;9:172-81. [PMID: 32042723 DOI: 10.18683/germs.2019.1173] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]